MedTrace Logo

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

NCT05541341 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-06-06

No results posted yet for this study

Summary

This will be a multicenter, national, non-interventional, prospective cohort study

Conditions

Interventions

OTHER

tisagenlecleucel

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
0 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-23
Primary Completion
2043-11-23
Completion
2043-11-23

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05541341 on ClinicalTrials.gov